Invokana (Canagliflozin)

Canagliflozin selectively blocks the sodium‑glucose co‑transporter‑2 (SGLT2) in the kidney’s proximal tubules. By inhibiting this transporter, the drug reduces reabsorption of filtered glucose, leading to increased urinary glucose loss and consequently lower blood glucose concentrations.

The appropriate dose of Invokana is determined by the prescribing healthcare professional based on individual patient factors such as renal function, concomitant medications and overall treatment goals. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of canagliflozin in pregnancy and lactation has not been established. The product is classified as pregnancy category unknown, and it is generally recommended to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare provider is essential.

To order Invokana, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Invokana belongs to the SGLT2 inhibitor class, which differs from metformin (biguanides) or sulfonylureas by promoting urinary glucose excretion rather than affecting hepatic glucose production or pancreatic insulin release. Compared with some alternatives, it offers additional benefits such as modest weight loss and cardiovascular risk reduction, but it also carries unique safety considerations.

Invokana tablets should be stored at ambient temperature, below 25 °C. Keep the medication in its original packaging, protect it from moisture and direct sunlight, and store it out of reach of children.

Invokana is taken orally, usually once daily in the morning, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include ketoacidosis (a metabolic emergency), severe dehydration, acute kidney injury, and rare cases of necrotizing fasciitis of the perineum (Fournier’s gangrene). Patients should be educated to recognize early symptoms and seek immediate medical attention if they occur.

Invokana is contraindicated in patients with severe renal impairment (eGFR below the approved threshold), end‑stage renal disease, or on dialysis. It should also be avoided in individuals with a known hypersensitivity to canagliflozin or any component of the formulation.